shareholders news from FierceBiotech
NewsBiovail focuses on CNS drugs
As the battle for Biovail continues, current CEO William Wells emphasized the company's focus on CNS drug development at Goldman Sachs' annual healthcare conference. Biovail is investing $600 million Read more...
Report: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Invitrogen, Applera agree on $6.7B merger
Two big suppliers to the drug development business are merging. Invitrogen has agreed to acquire all of the shares of Applera's Read more...
Sun to Taro: Too late to call off merger
It's too late to stop now, according the Sun Pharmaceuticals. Yesterday, Taro Pharmaceuticals said it was backing out of a planned merger with Sun because the move was not in the best interest of its Read more...
Going, going... Trimeris winds down ops
Faced with a patent fight that has frustrated efforts to find a buyer, Trimeris has begun to hand back out $80 million in cash as it winds down its operations. The Trimeris board has authorized Read more...
Amgen CEO: "I felt real economic pain"
What do you do when your biggest therapeutic earners are swooning, your stock price is down and analysts have turned scornful? Look for that silver lining. That was Read more...
Biogen squares off against Icahn in board battle
The war between Biogen Idec and Wall Street raider Carl Icahn is heating up. The Boston-based biotech has Read more...
Struggling VaxGen goes skeletal with cutbacks
With its planned merger involving Raven Biotechnologies on the rocks, a struggling VaxGen is Read more...
Troubled Amgen pays CEO $13.2M in compensation
With its shares plunging and regulators threatening its blockbuster anemia franchise, Amgen CEO Kevin Sharer (photo) nevertheless garnered $13.2 Read more...
Shareholders stymie VaxGen, Raven merger
VaxGen and Raven Biotechnologies are backing out of their proposed merger after "stronger than anticipated opposition" from shareholders. The companies say that while they initially thought Read more...
| Press ReleasesPress Release: Spherix Shareholders Support Company's Focus on Naturlose, BiotechnologySpherix Shareholders Support Company's Focus on Naturlose, Biotechnology Changes Approved for Board of Directors and Corporate Officers BELTSVILLE, Md., Aug. 16 -- Shareholders of Spherix Read more... |
Get more shareholders coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets